Reports outline osteoporosis therapy study findings from University of Basel

New investigation results, 'Simulation-based cost-utility analysis of population screening-based alendronate use in Switzerland,' are detailed in a study published in Osteoporosis International. "A simulation model adopting a health system perspective showed population-based screening with DXA, followed by alendronate treatment of persons with osteoporosis, or with anamnestic fracture and osteopenia, to be cost-effective in Swiss postmenopausal women from age 70, but not in men We assessed the cost-effectiveness of a population-based screen-and-treat strategy for osteoporosis (DXA followed by alendronate treatment if osteoporotic, or osteopenic in the presence of fracture), compared...

Want to see the full article?

• Purchase this article for only $3.00